Head of R&D for the New Analyte Ventures at Abbott Diabetes Care, Namvar Kiaie Joins Aditx Therapeutics’ Board of Directors...
August 25 2020 - 7:00AM
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
technologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
announced that it has appointed Namvar Kiaie to the Company’s Board
of Directors, effective as of July 2, 2020.
Aditxt’s Board now includes six members,
including Mr. Kiaie, who is an independent director in accordance
with the applicable rules of the Nasdaq Stock Market LLC. Mr. Kiaie
will serve as chair of the Compensation Committee.
Amro Albanna, Co-founder and Chief Executive
Officer of Aditxt, commented, “I am grateful that Namvar has agreed
to join our Board. Namvar has extensive experience leading research
and development efforts in the diagnostic industry and as an early
stage company, his insights and guidance will be very beneficial as
we work together to advance Aditxt’s development. On behalf of the
Board and the whole team, we welcome Namvar to the Aditxt family
and look forward to his contributions to our growth.”
Namvar Kiaie, Senior Director of R&D, Abbott
Diabetes Care, added, “I am extremely excited about the
technologies being developed by Aditxt and look forward to
contributing to the organization’s success.”
Mr. Kiaie has over 30 years of experience in the
medical industry and has been associated with Abbott Diabetes Care
since December 2005 in positions of increasing responsibility
including Director of Engineering from 2005-2007; R&D Director
from 2007-2010; and Senior Director of R&D from 2010-present.
He has been responsible for the development of diabetes management
related products and accessories, including continuous glucose
monitoring systems and data management software. Currently he is
leading the R&D organization responsible for the development of
next generation biosensing technologies in Abbott Diabetes Care’s
New Analyte Ventures. Prior to joining Abbott, Mr. Kiaie held
executive positions within the medical device industry implementing
programs from conception to production, including regulatory
responsibilities.
Mr. Kiaie graduated in 1985 with a Bachelor of
Science degree in Electrical Engineering and in 1986 with a Master
of Science degree in Electrical Engineering, both from the
University of California, Santa Barbara.
About Aditxt
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Words such as “may,” “might,” “will,”
“should,” “believe,” “expect,” “anticipate,” “estimate,”
“forecast,” “project,” “plan,” “intend” or similar expressions, or
statements regarding intent, belief, or current expectations,
including the Company’s expectations regarding the proposed
offering of the Company’s shares of common stock, including as to
the consummation of the offering described above and the size of
the offering are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company’s filings with the Securities and Exchange
Commission, including, but not limited to, risk factors relating to
its business contained therein. Thus, actual results could be
materially different. The Company expressly disclaims any
obligation to update or alter statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Relations:PCG Advisory:
Jeff RamsonChief Executive Officer646-762-4518IR@aditxt.com
www.aditxt.com |
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2024 to May 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2023 to May 2024